EBMT 2024 | A global view of transfusion-dependent thalassemia: standard of care, outcomes, and unmet needs
Ali Taher, MD, PhD, FRCP, American University of Beirut Medical Center, Beirut, Lebanon, summarizes a talk on the current standard of care, outcomes, and unmet needs for patients with transfusion-dependent thalassemia (TDT) worldwide. Blood transfusion and iron chelation therapy have significantly decreased the morbidity and mortality of patients with TDT. However, Prof. Taher highlights that the prevalence of TDT is high in areas of the world where access to therapy is low, meaning that 70-80% of patients globally do not have access to safe transfusion and iron chelation. Additionally, the lack of psychological support provided to patients must be addressed. This interview took place at the 50th Annual Meeting of the EBMT in Glasgow, Scotland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
